ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Online GLP-1 Weight Loss Program For Improved BMI & Long-Term Health Announced

OrderlyMeds, a fully online weight loss service, has announced a medically supervised GLP-1 therapy program for individuals who want to lose weight while remaining in good health.

-- Adding to its options for personalized weight loss programs, the platform is now accepting patients for its expanded GLP-1 therapies, which are designed to help individuals maintain a healthy BMI and reduce the risk of cardiovascular events. To ensure patient safety, OrderlyMeds works exclusively with US-based 503A pharmacies, including PerfectRx.

For more information, please visit https://orderlymeds.com/

GLP-1 (glucagon-like peptide-1) is a hormone that is produced in the small intestine and plays a vital role in lowering blood glucose concentrations and inducing feelings of satiation after eating. GLP-1 medications, such as semaglutide and tirzepatide, mimic this hormone and are often used for diabetic patients to reduce blood sugar and appetite. Practitioners like OrderlyMeds also offer semaglutide and tirzepatide as part of their weight loss programs, which combine medically supervised GLP-1 therapy and lifestyle changes to address the root causes of unhealthy weight gain.

In a typical one-year period on OrderlyMeds’ weight loss programs, patients will share their medical history and health goals with their provider and begin a GLP-1 therapy on the appropriate starting dose; the medication will be administered through weekly subcutaneous injections with an insulin syringe. Throughout the first three months, the team will monitor the patient to ensure that they are responding well to treatment and increase doses accordingly.

Beyond the three-month mark, patients will be encouraged to begin implementing OrderlyMeds’ lifestyle recommendations to form healthy habits to complement their GLP-1 medication; to aid with this, the team will provide the patient with an app to track their progress and help determine whether they should adjust their dosage, lifestyle strategies, and weight loss goals. Once at least ten months have passed, the program will begin focusing on sustained whole-body health - at this stage of the treatment, clients will be encouraged to set new wellness goals and consider their next steps for GLP-1 treatment.

A satisfied patient said, “OrderlyMeds has changed my life. I’ve lost 50 pounds, and because of that, I no longer have obstructive sleep apnea. I have more energy and I feel confident in myself. Their GLP-1 program is what made all the difference for me. I’m now the same size as I was in my early 20s.”

Interested parties can learn more by visiting https://orderlymeds.com/

Contact Info:
Name: Annie Dawson
Email: Send Email
Organization: OrderlyMeds
Address: 235 Ponce De Leon Pl Suite M347, Decatur, Georgia 30030, United States
Website: https://orderlymeds.com/

Source: PressCable

Release ID: 89183089

If you encounter any issues, discrepancies, or concerns regarding the content provided in this press release that require attention or if there is a need for a press release takedown, we kindly request that you notify us without delay at error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be available round-the-clock to address your concerns within 8 hours and take necessary actions to rectify any identified issues or guide you through the removal process. Ensuring accurate and reliable information is fundamental to our mission.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  205.27
-4.84 (-2.30%)
AAPL  266.18
+1.60 (0.60%)
AMD  196.60
-3.55 (-1.77%)
BAC  51.07
-1.99 (-3.75%)
GOOG  311.69
-3.21 (-1.02%)
META  637.46
-18.20 (-2.78%)
MSFT  384.47
-12.76 (-3.21%)
NVDA  191.55
+1.73 (0.91%)
ORCL  141.31
-6.77 (-4.57%)
TSLA  399.83
-11.99 (-2.91%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.